Interpretable machine learning models for early prediction of Crohn’s disease and ulcerative colitis in a nationwide health system
- 9 October 2026
- journal article
- Published by Oxford University Press (OUP) in Journal of Crohn's and Colitis
- Vol. 20 (10)
Abstract
Background & Aims: Delayed diagnosis of inflammatory bowel disease (IBD) is associated with worse outcomes. Existing prediction studies often rely on small cohorts or specialized biomarkers that limit scalability. We evaluated whether machine learning models based on routinely collected clinical data can predict future Crohn’s disease (CD) and ulcerative colitis (UC) years before diagnosis in a large population-based cohort. Methods: We conducted a retrospective study using electronic medical records from Maccabi Health Services (Israel), including 81 960 individuals (21 695 with IBD). Longitudinal laboratory tests, body mass index, demographics, and comorbidities were used to train Explainable Boosting Machine (EBM) models. Two frameworks were examined: (1) diagnosis-anchored prediction 0.5-2 years before diagnosis, and (2) age-based screening, estimating risk at predefined ages with future prediction windows. Performance was assessed using area under the receiver operating characteristic curve (AUROC) and relative risk (RR) in high-risk subgroups. Results: In diagnosis-anchored models, AUROC for CD ranged from 0.71 to 0.75 up to 2 years before diagnosis and from 0.62 to 0.64 for UC. In age-based screening, the best performance was observed at age 25 with a 1-11-year prediction window (AUROC 0.72 for CD; 0.70 for UC). Individuals in the top decile of predicted risk had an approximately 3-fold higher risk of future IBD, with RR remaining >2.5 for CD and >2.0 for UC for shorter windows. Kaplan–Meier analyses showed clear separation between high- and low-risk groups (P < .001). Conclusions: EBM models using routine clinical data can identify individuals at increased future IBD risk, supporting scalable, interpretable population-level risk stratification and earlier evaluation.Keywords
Funding Information
- Kahn Segol Maccabi Research and Innovative Institute
This publication has 25 references indexed in Scilit:
- A biomarker-stratified comparison of top-down versus accelerated step-up treatment strategies for patients with newly diagnosed Crohn's disease (PROFILE): a multicentre, open-label randomised controlled trialThe Lancet Gastroenterology & Hepatology, 2024
- Trends in Biochemical Parameters, Healthcare Resource and Medication Use in the 5 Years Preceding IBD Diagnosis: A Health Maintenance Organization Cohort StudyDigestive Diseases and Sciences, 2022
- Lifetime Economic Burden of Crohn’s Disease and Ulcerative Colitis by Age at DiagnosisClinical Gastroenterology and Hepatology, 2020
- Shorter Disease Duration Is Associated With Higher Rates of Response to Vedolizumab in Patients With Crohn’s Disease But Not Ulcerative ColitisClinical Gastroenterology and Hepatology, 2019
- The Impact of Inflammatory Bowel Disease on Work Productivity: Comparison of A Real-World Sample Of Patients With Crohn's Disease And Ulcerative ColitisValue in Health, 2016
- Neutrophils come of age in chronic inflammationCurrent Opinion in Immunology, 2012
- Development of the Crohnʼs disease digestive damage score, the Lémann scoreInflammatory Bowel Diseases, 2011
- Impact of inflammatory bowel disease on quality of life: Results of the European Federation of Crohn’s and Ulcerative Colitis Associations (EFCCA) patient surveyJournal of Crohn's and Colitis, 2007
- The Manitoba Inflammatory Bowel Disease Cohort Study: Prolonged Symptoms Before Diagnosis—How Much Is Irritable Bowel Syndrome?Clinical Gastroenterology and Hepatology, 2006
- Random ForestsMachine Learning, 2001